BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Genentech and Alnylam Advance Zilebesiran into Phase III Outcomes Trial for Hypertension

Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 – – ...

September 02, 2025 | News

Actinogen Confirms Commercial Tablet Formulation Of Xanamem Achieves Therapeutic Blood Levels

Actinogen Medical Limited (ASX: ACW) announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet form...

August 28, 2025 | News

Hope Biosciences Receives First RMAT Designation For Stem Cell Therapy In Multiple Sclerosis

Leading U.S. stem cell banking and cellular therapeutic manufacturer Hope Biosciences announces the U.S. Food and Drug Administration (FDA) has g...

August 28, 2025 | News

Akeso Reports Positive Phase 3 Results For Gumokimab In Ankylosing Spondylitis And Manfidokimab In Atopic Dermatitis

Akeso Inc. announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibod...

August 26, 2025 | News

Leads Biolabs Doses First Patient In Phase II Trial Of LBL-034, China’s First Potential GPRC5D-Targeted T-Cell Engager

Nanjing Leads Biolabs Co., Ltd. announced the first patient has been successfully dosed in the Phase Ⅱ trial of LBL-034 (GPRC5D/CD3 BsAb) following...

August 26, 2025 | News

AbbVie To Acquire Gilgamesh’s Lead Psychedelic Compound Bretisilocin For Up To $1.2 Billion

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of m...

August 26, 2025 | News

Antengene Reports Strong H1 2025 Results with Breakthrough Therapy Designation for ATG-022 and Robust Pipeline Progress

The Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate) demonstrated promising results, showing robust clinical efficacy and a fav...

August 25, 2025 | Company results

Lighthouse Pharma Secures $49.2M NIH Grant to Launch Phase 2 Alzheimer’s Trial in the United States

Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor Lighthouse Pharmaceuticals, a...

August 25, 2025 | News

SMSbiotech Launches First-in-Human Trial of Small Mobile Stem Cells for COPD in Australia

SMSbiotech, a San Diego–based leader in regenerative medicine, announced the initiation of its first-in-human Phase 1 clinical trial for C...

August 22, 2025 | News

Akeso Doses First Patient in Phase III COMPASSION-33 Trial of Cadonilimab for Perioperative Gastric Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-31...

August 21, 2025 | News

Sanofi and AstraZeneca’s Beyfortus Receives HSA Approval to Prevent RSV in Infants

Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety ...

August 20, 2025 | Regulatory

LabConnect Launches LabConnector™ to Transform Clinical Trial Data Management

LabConnect, LLC, a global leader in central laboratory services for clinical trials, announced the launch of LabConnector™, a powerful new techn...

August 20, 2025 | News

Mabwell Secures FDA IND Clearance for CDH17-Targeting ADC 7MW4911 in Advanced GI Cancers

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed CDH17-targeting ADC (R&D cod...

August 20, 2025 | News

Ascletis Reports 44.8% Weight Reduction in Obese Mouse Model with Combination of ASC47 and Novel Dual GLP-1R/GIPR Agonist ASC31

Combination of a low dose of ASC47 with ASC31, a novel peptide agonist targeting both GLP-1 receptor (GLP-1R) and GIP receptor (GIPR), ...

August 19, 2025 | News

Stay Connected